U.S. markets closed

Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session

Zacks Equity Research

Minerva Neurosciences, Inc. NERV was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock, which remained volatile and traded within the range of $3.71-$14.70 in the past one-month time frame, showed a sharp increase yesterday.

The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Minerva Neurosciences. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Minerva Neurosciences currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Minerva Neurosciences, Inc Price

Minerva Neurosciences, Inc Price

Minerva Neurosciences, Inc price | Minerva Neurosciences, Inc Quote

Investors interested in the Medical – Drugs industry may consider Avenue Therapeutics, Inc. ATXI, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Today's Best Stocks from Zacks 

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year. 

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Avenue Therapeutics, Inc. (ATXI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.